GeneDx Holdings Corp. reported its first quarter 2025 financial results on April 30, 2025, with total revenues reaching $87.1 million, a 42% increase year-over-year. Exome and genome test revenue grew by 62% year-over-year to $71.4 million, now representing 40% of all test results.
The company achieved its third consecutive quarter of profitability, reporting an adjusted net income of $7.7 million. Adjusted gross margin expanded to 69%, up from 61% in the first quarter of 2024, reflecting continued operational efficiencies and a favorable test mix.
GeneDx raised its full-year 2025 revenue guidance to between $360 million and $375 million, an increase from the previous range of $350 million to $360 million, with $3 million to $5 million expected from the Fabric Genomics acquisition. The company reaffirmed its outlook for at least 30% year-over-year exome and genome volume and revenue growth, and raised its adjusted gross margin guidance to between 66% and 68%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.